

G.N. RANZANI
FULL PAPERS

1. Tedaldi G, Pirini F, Tebaldi M, Zampiga V, Cangini I, Danesi R, Arcangeli V, Ravegnani M, Abou Khouzam R, Molinari C, Oliveira C, Morgagni P, Saragoni L, Bonafè M, Amadori D, Martinelli G, Falcini F, Ranzani GN, Calistri D. Multigene panel testing increases the number of loci associated with gastric cancer predisposition. *Cancers*. 2019; 11: 1340-1353
2. Rossi T, Tedaldi G, Petracci E, Abou Khouzam R, Ranzani GN, Morgagni P, Saragoni L, Monti M, Calistri D, Ulivi P, Molinari C. E-cadherin downregulation and microRNAs in sporadic intestinal-type gastric cancer. *Int J Mol Sci*. 2019; 20: 4452-4463
3. Mori G, Orena BS, Cultrera I, Barbieri G, Albertini AM, Ranzani GN, Carnevali I, Tibiletti MG, Pasca MR. Gut microbiota analysis in postoperative Lynch syndrome patients. *Front Microbiol*. 2019 Jul 30;10:1746. doi: 10.3389/fmicb.2019.01746. eCollection 2019.
4. Mori G, Rampelli S, Orena BS, Rengucci C, De Maio G, Barbieri G, Passardi A, Casadei Gardini A, Frassinetti GL, Gaiarsa S, Albertini AM, Ranzani GN, Calistri D, Pasca MR. Shifts of Faecal Microbiota During Sporadic Colorectal Carcinogenesis. *Sci Rep*. 2018; 8: 10329-10339
5. Molinari C, Abou Khouzam R, Salvi S, Rossi T, Ranzani GN, Calistri D. Detection of a CDH1 rare transcript variant in fresh-frozen gastric cancer tissues by chip-based Digital PCR. *J Vis Exp*. 2018 Feb 5;(132). doi: 10.3791/57066.
6. Weren RDA, van der Post RS, Vogelaar IP, van Krieken JHJM, Spruijt L, Lubinski J, Jakubowska A, Teodorczyk U, Aalfs CM, van Hest LP, Oliveira C, Kamping EJ, Schackert HK, Ranzani GN, Gómez García EB, Hes FJ, Holinski-Feder E, Genuardi M, Ausems MGEM, Sijmons RH, Wagner A, van der Kolk LE, Bjørnevoll I, Hoogerbrugge N, Ligtenberg MJL. Role of germline aberrations affecting *CTNNA1*, *MAP3K6* and *MYD88* in gastric cancer susceptibility. *J Med Genet*. 2018; 55: 669-674
7. Vetro A, Godin D, Lesende I, Limongelli I, Ranzani GN, Novara F, Bonaglia MC, Rinaldi B, Franchi F, Manolagos E, Lonardo F, Scarano F, Scarano G, Costantino L, Tedeschi S, Giglio S, Zuffardi O. Diagnostic application of a capture based NGS test for the concurrent detection of variants in sequence and copy number as well as LOH. *Clin Genet*. 2018; 93: 545-556
8. Vogelaar IP, van der Post RS, van Krieken JHJ, Spruijt L, van Zelst-Stams WA, Kets CM, Lubinski J, Jakubowska A, Teodorczyk U, Aalfs CM, van Hest LP, Pinheiro H, Oliveira C, Jhangiani SN, Muzny DM, Gibbs RA, Lupski JR, de Ligt J, Vissers LELM, Hoischen A, Gilissen C, van de Vorst M, Goeman JJ, Schackert HK, Ranzani GN, Molinaro V, Gómez García EB, Hes FJ, Holinski-Feder E, Genuardi M, Ausems MGEM, Sijmons RH, Wagner A, van der Kolk LE, Bjørnevoll I, Høberg-Vetti H, van Kessel AG, Kuiper RP, Ligtenberg MJL, Hoogerbrugge N. Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole exome sequencing. *Eur J Hum Genet*. 2017; 25: 1246-1252
9. Marabelli M, Gismondi V, Ricci MT, Vetro A, Abou Khouzam R, Rea V, Vitellaro M, Zuffardi O, Varesco L, Ranzani GN. A novel APC promoter 1B deletion shows a founder effect in Italian patients with classical familial adenomatous polyposis phenotype. *Genes Chromosomes Cancer*. 2017; 56: 846-854
10. Feroce I, Serrano D, Biffi R, Andreoni B, Galimberti V, Sonzogni A, Bottiglieri L, Botteri E, Trovato C, Marabelli M, Ranzani GN, Bonanni B. Hereditary Diffuse Gastric Cancer (HDGC) in two uncommon families. *Oncol Lett*. 2017; 14: 1671-1674

11. Abou Khouzam R, Molinari C, Salvi S, Marabelli M, Molinaro V, Orioli D, Saragoni L, Morgagni P, Calistri D, Ranzani GN. Digital PCR identifies changes in *CDH1* (E-cadherin) transcription pattern in intestinal-type gastric cancer. *Oncotarget*. 2017; 8: 18811-18820.
12. Marabelli M, Molinaro V, Abou Khouzam R, Berrino E, Panero M, Balsamo A, Venesio T, Ranzani GN. Colorectal Adenomatous Polyposis: Heterogeneity of Susceptibility Gene Mutations and Phenotypes in a Cohort of Italian Patients. *Genet Test Mol Biomarkers*. 2016; 20: 777-785.
13. Vogelaar IP, Ligtenberg MJ, van der Post RS, de Voer RM, Kets CM, Jansen TJ, Jacobs L, Schreiber G; International Gastric Cancer Genetics Group., de Vries IJ, Netea MG, Hoogerbrugge N. Recurrent candidiasis and early-onset gastric cancer in a patient with a genetically defined partial MYD88 defect. *Fam Cancer*. 2016; 15: 289-296.
14. De Gregori M, Diatchenko L, Ingelmo PM, Napolioni V, Klepstad P, Belfer I, Molinaro V, Garbin G, Ranzani GN, Alberio G, Normanno M, Lovisari F, Somaini M, Govoni S, Mura E, Bugada D, Niebel T, Zorzetto M, De Gregori S, Molinaro M, Fanelli G, Allegri M. Human Genetic Variability Contributes to Postoperative Morphine Consumption. *J Pain*. 2016; 17: 628-636.
15. Quadri M, Vetro A, Gismondi V, Marabelli M, Bertario L, Sala P, Varesco L, Zuffardi O, Ranzani GN. *APC* rearrangements in familial adenomatous polyposis: heterogeneity of deletion lengths and breakpoint sequences underlies similar phenotypes. *Fam Cancer*. 2015; 14: 41-49
16. Molinaro V, Pensotti V, Marabelli M, Feroce I, Barile M, Pozzi S, Laghi L, Serrano D, Bernard L, Bonanni B, Ranzani GN. Complementary molecular approaches reveal heterogeneous *CDH1* germline defects in Italian patients with hereditary diffuse gastric cancer (HDGC) syndrome. *Genes Chromosomes Cancer*. 2014; 53: 432-445.
17. De Gregori S, Minella CE, De Gregori M, Tinelli C, Ranzani GN, Govoni S, Allegri M, Regazzi M. Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain. *Ther Drug Monit*. 2014; 36: 335-344
18. De Gregori M, Garbin G, De Gregori S, Minella CE, Bugada D, Lisa A, Govoni S, Regazzi M, Allegri M, Ranzani GN. Genetic variability at *COMT* but not at *OPRM1* and *UGT2B7* loci modulates morphine analgesic response in acute postoperative pain. *Eur J Clin Pharmacol*. 2013; 69: 1651-1658
19. Venesio T, Balsamo A, Errichiello E, Ranzani GN, Risio M. Oxidative DNA damage drives carcinogenesis in *MUTYH*-associated-polyposis by specific mutations of mitochondrial and MAPK genes. *Mod Pathol*. 2013; 26: 1371-1381
20. Mura E, Govani S, Racchi M, Carossa V, Ranzani GN, Allegri M, van Schaik RHN. Consequences of the 118A>G polymorphism in the *OPRM1* gene: translation from bench to bedside? *J Pain Res*. 2013; 6: 331-353
21. Turco E, Ventura I, Minoprio A, Russo MT, Torreri P, Degan P, Molatore S, Ranzani GN, Bignami M, Mazzei F. Understanding the role of the Q338H *MUTYH* variant in oxidative damage repair. *Nucleic Acids Res*. 2013; 41: 4093-103
22. Lanni C, Garbin G, Lisa A, Biundo F, Ranzenigo A, Sinfioriani E, Cuzzoni G, Govoni S, Ranzani GN, Racchi M. Influence of *COMT* Val158Met Polymorphism on Alzheimer's Disease and Mild Cognitive Impairment in Italian Patients. *J Alzheimers Dis*. 2012; 32:919-26

23. Venesio T, Balsamo A, D'Agostino VG, Ranzani GN. MUTYH-associated polyposis (MAP), the syndrome implicating base excision repair in inherited predisposition to colorectal tumors. *Front Oncol.* 2012 Aug 2;2:83. doi: 10.3389/fonc.2012.00083. eCollection 2012.
24. De Gregori S, De Gregori M, Ranzani GN, Allegri M, Minella C, Regazzi M. Morphine metabolism, transport and brain disposition. *Metab Brain Dis.* 2012; 27: 1-5
25. De Gregori M, De Gregori S, Ranzani GN, Allegri M, Govoni S, Regazzi M. Individualizing pain therapy with opioids: the rational approach based on pharmacogenetics and pharmacokinetics. *Eur J Pain.* 2010; Suppl. 4: 245-250
26. D'Agostino VG, Minoprio A, Torreri P, Marinoni I, Bossa C, Petrucci TC, Albertini AM, Ranzani GN, Bignami M, Mazzei F. Functional analysis of *MUTYH* mutant proteins associated with familial adenomatous polyposis. *DNA Repair.* 2010; 9:700-7
27. De Gregori M, Allegri M, De Gregori S, Garbin G, Tinelli C, Regazzi M, Govoni S, Ranzani GN. How and why to screen for *CYP2D6* interindividual variability in patients under pharmacological treatments. *Curr Drug Metab.* 2010; 11:276-82
28. Molatore S, Russo MT, D'Agostino VG, Barone F, Matsumoto Y, Albertini AM, Minoprio A, Degan P, Mazzei F, Bignami M, Ranzani GN. *MUTYH* mutations associated with familial adenomatous polyposis: functional characterization by a mammalian cell-based assay. *Hum Mutat.* 2010; 31:159-66
29. Ranzani GN, De Gregori S, De Gregori M, Govoni S, Regazzi M. Interindividual variability of drug transporters: impact on opioid treatment in chronic renal failure. *Eur J Pain.* 2009; Suppl. 3:21-28
30. De Gregori S, De Gregori M, Ranzani GN, Borghesi A, Regazzi M, Stronati M. Drug transporters and renal drug disposition in the newborn. *J Matern Fetal Neonatal Med.* 2009; Suppl.3:31-37
31. Klug SJ, Rensing M, Koenig J, Abba MC, Agorastos T, Brenna SM, Ciotti M, Das BR, Del Mistro A, Dybikowska A, Giuliano AR, Gudleviciene Z, Gyllensten U, Haws AL, Helland A, Herrington CS, Hildesheim A, Humbey O, Jee SH, Kim JW, Madeleine MM, Menczer J, Ngan HY, Nishikawa A, Niwa Y, Pegoraro R, Pillai MR, Ranzani G, Rezza G, Rosenthal AN, Roychoudhury S, Saranath D, Schmitt VM, Sengupta S, Settheetham-Ishida W, Shirasawa H, Snijders PJ, Stoler MH, Suárez-Rincón AE, Szarka K, Tachezy R, Ueda M, van der Zee AG, von Knebel Doeberitz M, Wu MT, Yamashita T, Zehbe I, Blettner M. *TP53* codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. *Lancet Oncol.* 2009; 10:772-784
32. Govoni S, Regazzi M, Ranzani GN. Pain and the pharmacogenetics at the fuzzy border between pain physiopathology and pain treatment. *Eur J Pain.* 2008; Suppl. 2:5-12
33. Cattaneo F, Molatore S, Mihalatos M, Apessos A, Venesio T, Bione S, Grignani P, Nasioulas G, Ranzani GN. Heterogeneous molecular mechanisms underlie attenuated familial adenomatous polyposis. *Genet Med.* 2007; 9:836-841
34. Ponz de Leon M, Bertario L, Genuardi M, Lanza G, Oliani C, Ranzani GN, Rossi GB, Varesco L, Venesio T, Viel A. Identification and classification of HNPCC (Lynch Syndrome): adapting old concepts to recent advancements. Report from the Italian Association for the Study of Hereditary Colorectal Tumors Consensus Group. *Dis Colon Rectum.* 2007; 50:2126-2134

35. Venesio T, Balsamo A, Sfiligoi C, Fuso L, Molatore S, Ranzani GN, Risio M. Constitutional high expression of an *APC* mRNA isoform in a subset of Attenuated Familial Adenomatous Polyposis patients. *J Mol Med.* 2007; 85:301-308
36. Cattaneo F, Venesio T, Molatore S, Russo A, Fiocca R, Frattini M, Scovassi AI, Ottini L, Bertario L, Ranzani GN. Functional analysis and case-control study of -160C/A polymorphism in the E-cadherin gene promoter: association with cancer risk. *Anticancer Res.* 2006; 26:4627-4632
37. Perri F, Piepoli A, Bonvicini C, Gentile A, Quitadamo M, Di Candia M, Cotugno R, Cattaneo F, Zagari MR, Ricciardiello L, Gennarelli M, Bazzoli F, Ranzani GN, Andriulli A. Cytokine gene polymorphisms in gastric cancer patients from two Italian areas at high and low cancer prevalence. *Cytokine.* 2005; 30:293-302
38. Bardella C, Costa B, Maggiora P, Patane' S, Olivero M, Ranzani GN, De Bortoli M, Comoglio PM, Di Renzo MF. Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. *Cancer Res.* 2004; 64:5154-5161
39. Molatore S, Ranzani GN. Genetics of colorectal polyps. *Tech Coloproctol.* 2004; 8 Suppl 2: 240-S243
40. Venesio T, Molatore S, Cattaneo F, Arrigoni A, Risio M, Ranzani GN. High Frequency of *MYH* Gene Mutations in a Subset of Familial Adenomatous Polyposis Patients. *Gastroenterology.* 2004; 126:1681-1685
41. Gorrini C, Donzelli M, Torriglia A, Supino R, Brison O, Bernardi R, Negri C, Denegri M, Counis MF, Ranzani GN, Scovassi AI. Effect of apoptogenic stimuli on colon carcinoma cell lines with a different c-myc expression level. *Int J Mol Med.* 2003; 11:737-742
42. Venesio T, Balsamo A, Rondo-Spaudo M, Varesco L, Risio M, Ranzani GN. *APC* haploinsufficiency, but not *CTNNB1* or *CDH1* gene mutations, account for a fraction of familial adenomatous polyposis patients without *APC* truncating mutations. *Lab Invest.* 2003; 83:1859-1866
43. Candusso ME, Luinetti O, Villani L, Alberizzi P, Klersy C, Fiocca R, Ranzani GN, Solcia E. Loss of heterozygosity at 18q21 region in gastric cancer involves a number of cancer-related genes and correlates with stage and histology but lacks independent prognostic value. *J Pathol.* 2002; 197:44-50
44. Duval A, Reperant M, Compoin A, Seruca R, Ranzani GN, Iacopetta B, Hamelin R. Target gene mutation profile differs between gastrointestinal and endometrial tumors with mismatch repair deficiency. *Cancer Res.* 2002; 62:1609-1612
45. Laghi L, Ranzani GN, Bianchi P, Mori A, Heinemann K, Orbetegli O, Spaudo MR, Luinetti O, Franciconi S, Roncalli M, Solcia E, Malesci A. Frameshift mutations of human gastrin receptor gene (*hGARE*) in gastrointestinal cancers with microsatellite instability. *Lab Invest.* 2002; 82:265-271
46. Birindelli S, Perrone F, Oggionni M, Lavarino C, Pasini B, Vergani B, Ranzani GN, Pierotti MA, Pilotti S. *Rb* and *TP53* pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. *Lab Invest.* 2001; 81:833-844
47. Calin G, Ranzani GN, Amadori D, Herlea V, Matei I, Barbanti-Brodano G, Negrini M. Somatic frameshift mutations in the Bloom syndrome *BLM* gene are frequent in sporadic gastric carcinomas with microsatellite mutator phenotype. *BMC Genet.* 2001; 2:14-20

48. Fiocca R, Luinetti O, Villani L, Mastracci L, Quilici P, Grillo F, Ranzani GN. Molecular mechanisms involved in the pathogenesis of gastric carcinoma: interactions between genetic alterations, cellular phenotype and cancer histotype. *Hepatogastroenterology*. 2001; 48:1523-1530
49. Scovassi AL, Pellegata NS, Di Stefano L, Padovan L, Negri C, Prospero E, Riva F, Ciomei M, Ranzani GN. Effects of topoisomerase II inhibitors on gastric cancer cells characterized by different genetic lesions. *Anticancer Res*. 2001; 21:2803-2808
50. Birindelli S, Tragni G, Bartoli C, Ranzani GN, Rilke F, Pierotti MA, Pilotti S. Detection of microsatellite alterations in the spectrum of melanocytic nevi in patients with or without individual or familial history of melanoma. *Int J Cancer*. 2000; 86:255-261
51. Calistri D, Presciuttini S, Buonsanti G, Radice P, Gazzoli I, Pensotti V, Sala P, Eboli M, Andreola S, Russo A, Pierotti M, Bertario L, Ranzani GN. Microsatellite instability in colorectal cancer patients with suspected genetic predisposition. *Int J Cancer*. 2000; 89:87-91
52. Tenti P, Vesentini N, Rondo Spauolo M, Zappatore R, Migliora P, Carnevali L, Ranzani GN. *p53* codon 72 polymorphism does not affect the risk of cervical cancer in patients from Northern Italy. *Cancer Epidemiol Biomarkers Prev*. 2000; 9:435-438
53. Duval A, Iacopetta B, Ranzani GN, Lothe RA, Thomas G, Hamelin R. Variable mutation frequencies in coding repeats of *TCF-4* and other target genes in colon, gastric and endometrial carcinomas showing microsatellite instability. *Oncogene*. 1999; 18:6806-6809
54. Formantici C, Orlandi R, Ronchini C, Pilotti S, Ranzani GN, Colnaghi MI, Ménard S. Absence of microsatellite instability in breast carcinomas with both *p53* and *c-erbB-2* alterations. *J Pathol*. 1999; 187:424-27
55. Rudan I, Campbell H, Ranzani GN, Strnad M, Vorko-Jović A, John V, Kern J, Ivanković D, Stevanović R, Vuckov S, Vuletić S, Rudan P. Cancer incidence in eastern Adriatic isolates, Croatia: examples from the islands of Krk, Cres, Losinj, Rab and Pag. *Coll Antropol*. 1999; 23:547-556
56. Rudan I, Ranzani GN, Strnad M, Vorko-Jović A, John V, Unusić J, Kern J, Ivanković D, Stevanović R, Vuletić S, Rudan P. Surname as 'cancer risk' in extreme isolates: example from the island of Lastovo, Croatia. *Coll Antropol*. 1999; 23:557-569
57. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res*. 1998; 58:5248-5257
58. Buonsanti G, Presciuttini S, Radice P, Pierotti MA, Bertario L, Ranzani GN. Rapid assessment of replication error phenotype in gastric cancer. *Diagn Mol Pathol*. 1998; 7:168-173
59. Luinetti O, Fiocca R, Villani L, Alberizzi P, Ranzani GN, Solcia E. Genetic pattern, histological structure, and cellular phenotype in early and advanced gastric cancers: evidence for structure-related genetic subsets and for loss of glandular structure during progression of some tumors. *Hum Pathol*. 1998; 29:702-709
60. Sessa F, Bonato M, Bioni D, Ranzani GN, Capella C. *Ki-ras* and *p53* gene mutations in pancreatic ductal carcinoma: a relationship with tumor phenotype and survival. *Eur J Histochem*. 1998; 42: 67-76

61. Tenti P, Pavanello S, Padovan L, Spinillo A, Vesentini N, Zappatore R, Migliora P, Zara C, Ranzani GN, Carnevali L. Analysis and clinical implications of *p53* gene mutations and human papillomavirus type 16 and 18 infection in primary adenocarcinoma of the uterine cervix. *Am J Pathol.* 1998; 152:1057-1063
62. Amadori D, Maltoni M, Volpi A, Nanni O, Scarpi E, Renault B, Pellegata NS, Gaudio M, Magni E, Ranzani GN. Gene amplification and proliferative kinetics in relation to prognosis of patients with gastric carcinoma. *Cancer.* 1997; 79:226-232
63. Buonsanti G, Calistri D, Padovan L, Luinetti O, Fiocca R, Solcia E, Ranzani GN. Microsatellite instability in intestinal-and diffuse-type gastric carcinoma. *J Pathol.* 1997; 182:167-173
64. Pensotti V, Radice P, Presciuttini S, Calistri D, Gazzoli I, Grimalt Perez A, Mondini P, Buonsanti G, Sala P, Rossetti C, Ranzani GN, Bertario L, Pierotti MA. Mean age of tumor onset in Hereditary Nonpolyposis Colorectal Cancer (HNPCC) families correlates with the presence of mutations in DNA mismatch repair genes. *Genes Chromosomes Cancer.* 1997; 19:135-142
65. Baffa R, Negrini M, Mandes B, Ruge M, Ranzani GN, Hirohashi S, Croce CM. Loss of Heterozygosity for chromosome 11 in adenocarcinoma of the stomach. *Cancer Res.* 1996; 56:268-272
66. Campomenosi P, Ottaggio L, Moro F, Urbini S, Bogliolo M, Zunino A, Camoriano A, Inga A, Gentile SL, Pellegata NS, Bonassi S, Bruzzone E, Iannone R, Pisani R, Menichini P, Ranzani GN, Bonatti S, Abbondandolo A, Fronza G. Study on aneuploidy and *p53* mutations in astrocytomas. *Cancer Genet Cytogenet.* 1996; 88:95-102
67. Pellegata NS, Ranzani GN. The significance of *p53* mutations in human cancers. *Eur J Histochem.* 1996; 40:273-282
68. Ranzani GN. Genetic alterations in gastric cancer. *Ann Ist Super Sanita.* 1996; 32:101-110
69. Renault B, Calistri D, Buonsanti G, Nanni O, Amadori D, Ranzani GN. Microsatellite instability and mutations of *p53* and *TGF-beta RII* genes in gastric cancer. *Hum Genet.* 1996; 98:601-607
70. Solcia E, Fiocca R, Luinetti O, Villani L, Padovan L, Calistri D, Ranzani GN, Chiaravalli A, Capella C. Intestinal and diffuse gastric cancers arise in a different background of *Helicobacter pylori* gastritis through different gene involvement. *Am J Surg Pathol.* 1996; 20: 8-22
71. Ranzani GN, Luinetti O, Padovan LS, Calistri D, Renault B, Burrel M, Amadori D, Fiocca R, Solcia E. *p53* gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type. *Cancer Epidemiol Biomarkers Prev.* 1995; 4: 223-231
72. Tenti P, Romagnoli S, Silini E, Pellegata NS, Zappatore R, Spinillo A, Zara C, Ranzani GN, Carnevali L. Analysis and clinical implications of *K-ras* gene mutations and infection with papillomavirus type 16 and 18 in primary adenocarcinoma of the uterine cervix. *Int J Cancer.* 1995; 64:9-13
73. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, Ranzani GN. *K-Ras* and *p53* gene mutations in pancreatic cancer: ductal and nonductal tumours progress through different genetic lesions. *Cancer Res.* 1994; 54:1556-1560
74. Sessa F, Solcia E, Capella C, Bonato M, Scarpa A, Zamboni G, Pellegata NS, Ranzani GN, Rickaert F, Klöppel G. Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an

investigation of tumour cell differentiation and *K-ras*, *p53* and *c-erbB-2* abnormalities in 26 patients. *Virchows Arch.* 1994; 425:357-367

75. Silini EM, Bosi F, Pellegata NS, Volpato G, Romano A, Nazari S, Tinelli C, Ranzani GN, Solcia E, Fiocca R. *K-ras* gene mutations: an unfavorable prognostic marker in stage I lung adenocarcinoma. *Virchows Arch.* 1994; 424:367-373
76. Tenti P, Romagnoli S, Pellegata NS, Zappatore R, Giunta P, Ranzani GN, Carnevali L. Primary retroperitoneal mucinous cystoadenocarcinomas: an immunohistochemical and molecular study. *Virchows Arch.* 1994; 424:53-57
77. De Benedetti L, Varesco L, Pellegata NS, Losi L, Gismondi V, Casarino L, Sciallero S, Bonelli L, Biticchi R, Bafico A, Masetti E, James R, Heouaine A, Ranzani GN, Aste H, Ferrara GB. Genetic events in sporadic colorectal adenomas; *K-ras* and *p53* heterozygous mutations are not sufficient for malignant progression. *Anticancer Res.* 1993; 13:667-670
78. Mor O, Ranzani GN, Ravia Y, Rotman G, Gutman M, Manor A, Amadori D, Houldsworth J, Hollstein M, Schwab M, Shiloh Y. DNA amplification in human gastric carcinomas. *Cancer Genet Cytogenet.* 1993; 65:111-114
79. Ranzani GN, Renault B, Pellegata NS, Fattorini P, Magni E, Bacci F, Amadori D. Loss of heterozygosity and *K-ras* gene mutations in gastric cancer. *Hum Genet.* 1993; 92:244-249
80. Renault B, van den Broek M, Fodde R, Wijnen J, Pellegata NS, Amadori D, Khan PM, Ranzani GN. Base transitions are the most frequent genetic changes at *p53* in gastric cancer. *Cancer Res.* 1993; 53:2614-2617
81. Pellegata NS, Losekoot M, Fodde R, Pugliese V, Saccomanno S, Renault B, Bernini LF, Ranzani GN. Detection of *K-ras* mutations by denaturing gradient gel electrophoresis (DGGE): a study on pancreatic cancer. *Anticancer Res.* 1992; 12:1731-1735
82. Shiloh Y, Mor O, Manor A, Bar-Am I, Rotman G, Eubanks J, Gutman M, Ranzani GN, Houldsworth J, Evans G, Avivi L. DNA sequences amplified in cancer cells: an interface between tumor biology and human genome analysis. *Mutat Res.* 1992; 276:329-337
83. Pellegata NS, Bergamaschi G, Amadori D, Aloia A, Ballarini P, Del Senno L, Amaducci L, Ranzani GN. A 5'-truncated *c-myc* gene variant not associated with a risk of cancer. *Hum Genet.* 1991; 87:579-582
84. Avato FM, Peloso G, Lucarini N, Ballarini P, Aloia A, Previderè C, Ranzani GN. Red cell and serum polymorphisms in the Oltrepò Pavese population (northern Italy). *Gene Geogr.* 1990; 4:135-137
85. Ranzani GN, Pellegata NS, Previderè C, Saragoni A, Vio A, Maltoni M, Amadori D. Heterogeneous protooncogene amplification correlates with tumor progression and presence of metastases in gastric cancer patients. *Cancer Res.* 1990; 50:7811-7814
86. De Paoli F, Salerno-Mele P, Ranzani GN, Mazzucco M, Belvedere MC. IgA serum levels and HLA complement markers in gastric cancer patients. *Cancer Detect Prev.* 1988; 12:389-393
87. Biondi G, Battistuzzi G, Rickards O, Carli A, De Stefano GF, Santachiara-Benerecetti SA, Ranzani GN, Beretta M, Astolfi P, Santolamazza C. Migration pattern and genetic marker distribution of the Afro-American population of Bluefields, Nicaragua. *Ann Hum Biol.* 1988; 15:399-412

88. Ranzani GN, Salerno-Mele P, Maltoni M, Talarico D, Della Valle G, Amadori D. Study of the *c-Ha-ras-1* locus polymorphism in an Italian population with high incidence of gastric cancer. *Mol Biol Med.* 1988; 5:145-153
89. Barberio C, Ranzani GN, Beretta M, Antonini G, Mura G, Pardini R, Zanella A, Santachiara-Benerecetti AS. A study of several red cell enzyme markers in two samples of the Italian population. Report of new *CAI* and *PGD* variant phenotypes. *Gene Geogr.* 1987; 1:31-40.
90. Ranzani GN, Brdicka R, Antonini G, Pardini R, Santachiara-Benerecetti AS. Electrophoretic subtyping of phosphoglucomutase locus 1 (*PGMI*) polymorphism in the Italian and Czechoslovakian populations. *Hum Hered.* 1985; 35:273-278
91. Ranzani GN, Bernini LF, Crippa M. Inheritance of *rDNA* spacer length variants in man. *Mol Gen Genet.* 1984; 196:141-145
92. Morpurgo G, Modiano G, Arese P, Ranzani GN, Felicetti L, Tozzi F, Mura G, Santachiara-Benerecetti AS. Population genetic studies in Sikkim. *J Hum Evol.* 1983; 12:425-437
93. Santachiara-Benerecetti AS, Ranzani GN, Antonini G, Beretta M. Subtyping of phosphoglucomutase locus 1 (*PGMI*) polymorphism in some populations of Rwanda: description of variant phenotypes, "haplotype" frequencies, and linkage disequilibrium data. *Am J Hum Genet.* 1982; 34:337-348
94. Ranzani GN, Antonini G, Beretta M, Santachiara Benerecetti AS. A study of ten red cell enzymatic markers in the Naples' population. Report of a new GPT variant phenotype. *Z Rechtsmed.* 1982; 89:89-95.
95. Santachiara-Benerecetti AS, Ranzani GN, Antonini G. Subtyping of human red cell phosphoglucomutase locus 1 (*PGMI*) polymorphism: a third *PGMI*(1) allele common among Twa Pygmies from North Rwanda. *Am J Hum Genet.* 1981; 33:817-822
96. Santachiara-Benerecetti AS, Beretta M, Negri M, Ranzani G, Antonini G, Barberio C, Modiano G, Cavalli-Sforza LL. Population genetics of red cell enzymes in Pygmies: a conclusive account. *Am J Hum Genet.* 1980; 32:934-954
97. Ranzani G, Antonini G, Santachiara-Benerecetti AS. Red cell glyoxalase I polymorphism in Italians. Report of a variant phenotype. *Hum Hered.* 1979; 29:261-264
98. Ranzani G, Beretta M, Santachiara Benerecetti AS. The polymorphism of red cell esterase D in Italy. *Hum Hered.* 1978; 28:147-150
99. Santachiara-Benerecetti AS, Ranzani GN, Antonini G. Studies on African pygmies. V. Red cell acid phosphatase polymorphism in Babinga pygmies: high frequency of ACPR allele. *Am J Hum Genet.* 1977; 29:635-638
100. Beretta M, Barberio C, Ranzani G, Bertolotti EG. An analysis of red cell enzymatic markers in the province of Bologna (Italy). *Hum Hered.* 1977; 27:352-355
101. Ranzani G, Bertolotti E, Santachiara-Benerecetti AS. The polymorphism of red cell uridine monophosphate kinase in two samples of the Italian population. *Hum Hered.* 1977; 27:332-335

102. Pedrini AM, Ranzani G, Pedrali Noy GC, Spadari S, Falaschi A. novel endonuclease of human cells specific for single-stranded DNA. *Eur J Biochem.* 1976; 70:275-283
103. Santachiara-Benerecetti AS, Baur EW, Beretta M, Ranzani G, Morpurgo G, Carter ND, D'Udine B, Ranjit SK, Modiano G. A study of several genetic biochemical markers in Sherpas with description of some variant phenotypes. *Hum Hered.* 1976; 26:351-359

Invited book articles and book chapters

1. G.N. Ranzani (1998). Geni oncosoppressori e tumori ereditari. In: *Genetica Generale e Umana*. Padova: Piccin Editore, vol. II, p. 367-385
2. M. D. Cappellini, M. Sampietro, L. F. Bernini, Ranzani G.N. (1982). F-Cell distribution in normals and in Heterocellular HPFH (Swiss Type). In: D. J. Weatherall et al. *Advances in Red Cell Biology*; Raven Press. p. 271-278, New York

Popular scientific articles

1. Cini G, Ranzani GN, Cannizzaro R, Chiappa A, Fassan M, Fornasarig M, Roncucci L, Sanchez Mete L, Tibiletti MG, Viel A (2019). La sindrome di Lynch raccontata dalla Associazione AIFEG. *MR La Rivista Italiana delle Malattie Rare* anno III - n. 2 - giugno 2019, p. 16-24
2. Ranzani G N (2007). La predisposizione ereditaria ai tumori del colonretto: analisi genetico-molecolari delle poliposi e della sindrome di Lynch. *RENDICONTI*, Istituto Lombardo - Accademia di Scienze e Lettere, vol. 141, p. 197-204
3. Ranzani GN (1999). Genetica molecolare dei tumori e nuovi approcci terapeutici. *BIOTEC*, vol. 4, p. 37-45
4. Ranzani GN (1997). Predisposizione genetica ai tumori. *BIOTEC*, vol. 2, p. 25-32